As of 31 July 2023, the National Clinical Evidence Taskforce is no longer funded. The COVID-19 and MPX guidelines are still accessible online, but are not currently being updated.
For more information and the latest developments in Australian living evidence visit livingevidence.org.au
The Taskforce uses a world-leading ‘living evidence’ approach, which combines rigorous, evidence-based methods and rapid, weekly updating. This enables the Taskforce to modify and update recommendations rapidly in response to the publication of new research evidence.
The guidelines use the GRADE methods and are designed to meet Australian NHMRC standards.
Relevant new questions to be addressed are continually sought from stakeholders and practitioners. For prioritised questions, the evidence is actively monitored and updated. Evidence surveillance combines horizon scans and targeted searches.
An evidence team appraises and synthesises evidence and prepares evidence-to-decision frameworks to inform development of recommendations by multidisciplinary clinical panels.
A guidelines leadership group oversees the development of recommendations by these expert panels and is advised by a consumer panel.
After initial approval by the Guidelines Leadership Group, all recommendations require 100% consensus by our 35 member organisations.
Endorsed recommendations are published online in MAGICapp and disseminated through traditional and social media channels.
Find out more about evidence-based guideline development and GRADE methods: